S'abonner

The First Brazilian Cardiovascular Registry of Atrial Fibrillation: Primary Results of the RECALL Study - 13/09/23

Doi : 10.1016/j.ahj.2023.06.007 
Renato D. Lopes, MD, MHS, PhD a, b, , Pedro G.M. de Barros e Silva, MD, MHS, PhD a, c, d, Conrado Roberto Hoffmann Filho, MD, MSc e, Margaret Assad Cavalvante, MD, MSc f, Claudia Madeira Miranda, MD, MSc g, Rodrigo Barbosa Esper, MD, PhD h, Gustavo Glotz de Lima, MD, PhD i, Luiz Eduardo Fonteles Ritt, MD, PhD j, k, Rose Mary Ferreira Lisboa da Silva, MD, PhD l, Marcelo A. Nakazone, MD, PhD m, Adail Paixão Almeida, MD n, Ricardo Pavanello, MD, PhD c, Carlos Eduardo Batista de Lima, MD, PhD o, Luciano Marcelo Backes, MD p, Lucas Hollanda Oliveira, MD, MSc q, Olga Ferreira de Souza, MD, PhD r, Adalberto Menezes Lorga Filho, MD, PhD s, Epotamenides Maria Good God, MD, PhD t, José Carlos Moura Jorge, MD, PhD u, Alcirley de Almeida Luiz, MD v, w, Simone Fialho Pereira Pimentel Martins, MD x, Rogério Carregoza Dantas, MD, MSc y, Ricardo D´Oliveira Vieira, MD, PhD z, Leandro Ioschpe Zimerman, MD, PhD aa, Álvaro Rabelo Alves Júnior, MD bb, Márcio Jansen de Oliveira Figueiredo, MD, PhD cc, Samara Pinheiro do Carmo Gomes, BSc c, Lucas Martins de Lima, RMD c, Lucas Petri Damiani, PhD a, c, Ricardo Alkmim Teixeira, MD, PhD dd, ee, ff, Alexandro Alves Fagundes, MD dd, Eduardo Benchimol Saad, MD, PhD dd, gg, hh
on behalf of the

RECALL Investigators

a Brazilian Clinical Research Institute, Sao Paulo, SP, Brazil 
b Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
c HCOR Research Institute, São Paulo, SP, Brazil 
d Hospital Samaritano Paulista, São Paulo, SP, Brazil 
e Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil 
f Hospital Regional de Presidente Prudente, Presidente Prudente, SP, Brazil 
g Hospital Madre Teresa Belo Horizonte, MG, Brazil 
h Instituto Prevent Senior, Sao Paulo, SP, Brazil 
i Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil 
j D'or Research Institute, Hospital Cardio Pulmomar, Salvador, BA, Brazil 
k Bahiana School of Medicine and Public Health, Salvador, BA, Brazil 
l Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil 
m Faculdade de Medicina de Sao José do Rio Preto, Sao José do Rio Preto, SP, Brazil 
n Unidade Médico Cirúrgica – UNIMEC, Vitória da Conquista, BA, Brazil 
o Hospital Universitário da Universidade Federal do Piauí, Teresina, PI, Brazil 
p Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil 
q Hospital Ana Nery, Salvador, BA, Brazil 
r Hospital Copa D'Or, Rio de Janeiro, RJ, Brazil 
s Instituto de Moléstias Cardiovasculares, São José do Rio Preto, SP, Brazil 
t Hospital Socor, Belo Horizonte, MG, Brazil 
u Clínica da Irmandade da Santa Casa de Curitiba, Curitiba, PR, Brazil 
v Universidade Estadual do Oeste do Paraná, Cascavel, PR, Brazil 
w Hospital Universitário do Oeste do Paraná, Cascavel, PR, Brazil 
x Centro Municipal de Especialidades da Prefeitura Municipal de Vitória, Vitória, ES, Brazil 
y Hospital Santo Antônio Curvelo (Irmandade de Santo Antonio de Curvelo), Curvelo, MG, Brazil 
z Hospital e Clínica São Roque, Ipiaú, BA, Brazil 
aa Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil 
bb Fundação Bahiana de Cardiologia, Salvador, BA, Brazil 
cc Hospital de Clínicas da Universidade Estadual de Campinas, Campinas, SP, Brazil 
dd Sociedade Brasileira de Arritmias Cardíacas, Sao Paulo, SP, Brazil 
ee Hospital Renascentista, Pouso Alegre, MG, Brazil 
ff Universidade do Vale do Sapucaí, Pouso Alegre, MG, Brazil 
gg Hospital Pró-Cardíaco, Rio de Janeiro, RJ, Brazil 
hh Hospital Samaritano Botafogo, Rio de Janeiro, RJ, Brazil 

Reprint requests: Renato D. Lopes, MD, MHS, PhD, Duke Clinical Research Institute, 300 West Morgan Street, Suite 800, Durham, NC 27701.Duke Clinical Research Institute300 West Morgan Street, Suite 800DurhamNC27701

Résumé

Background

It is estimated that atrial fibrillation (AF) affects approximately 1.5 million people in Brazil; however, epidemiological data are limited. We sought to evaluate the characteristics, treatment patterns, and clinical outcomes in patients with AF in Brazil by creating the first nationwide prospective registry.

Methods

RECALL was a multicenter, prospective registry that included and followed for 1 year 4,585 patients with AF at 89 sites across Brazil from April 2012 to August 2019. Patient characteristics, concomitant medication use, and clinical outcomes were analyzed using descriptive statistics and multivariable models.

Results

Of 4,585 patients enrolled, the median age was 70 (61, 78) years, 46% were women, and 53.8% had permanent AF. Only 4.4% of patients had a history of previous AF ablation and 25.2% had a previous cardioversion. The mean (SD) CHA2DS2-VASc score was 3.2 (1.6); median HAS-BLED score was 2 (2, 3). At baseline, 22% were not on anticoagulants. Of those taking anticoagulants, 62.6% were taking vitamin K antagonists and 37.4% were taking direct oral anticoagulants. The primary reasons for not using an oral anticoagulant were physician judgment (24.6%) and difficulty in controlling (14.7%) or performing (9.9%) INR. Mean (SD) TTR for the study period was 49.5% (27.5). During follow-up, the use of anticoagulants and INR in the therapeutic range increased to 87.1% and 59.1%, respectively. The rates/100 patient-years of death, hospitalization due to AF, AF ablation, cardioversion, stroke, systemic embolism, and major bleeding were 5.76 (5.12-6.47), 15.8 (14.6-17.0), 5.0 (4.4-5.7), 1.8 (1.4-2.2), 2.77 (2.32-3.32), 1.01 (0.75-1.36), and 2.21 (1.81-2.70). Older age, permanent AF, New York Heart Association class III/IV, chronic kidney disease, peripheral arterial disease, stroke, chronic obstructive pulmonary disease, and dementia were independently associated with increased mortality while the use of anticoagulant was associated with lower risk of death.

Conclusions

RECALL represents the largest prospective registry of patients with AF in Latin America. Our findings highlight important gaps in treatment, which can inform clinical practice and guide future interventions to improve the care of these patients.

Le texte complet de cet article est disponible en PDF.

Plan


© 2023  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 264

P. 97-105 - octobre 2023 Retour au numéro
Article précédent Article précédent
  • Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study
  • Kamil Bujak, Pablo Vidal-Cales, Rami Gabani, Riccardo Rinaldi, Josep Gomez-Lara, Luis Ortega-Paz, Victor Jimenez-Diaz, Marcelo Jimenez-Kockar, Pilar Jimenez-Quevedo, Roberto Diletti, Gianluca Campo, Antonio Silvestro, Jaume Maristany, Xacobe Flores, Loreto Oyarzabal, Antonio De Miguel-Castro, Andrés Iñiguez, Luis Nombela-Franco, Alfonso Ielasi, Maurizio Tespili, Mattie Lenzen, Simone Biscaglia, Soheil Al-Shaibani, Rafael Romaguera, Joan Antoni Gomez-Hospital, Mariusz Gasior, Patrick W. Serruys, Manel Sabate, Salvatore Brugaletta
| Article suivant Article suivant
  • Hemodialysis and its impact on patient characteristics, microbiology, cardiac surgery, and mortality in infective endocarditis
  • Anna Stahl, Eva Havers-Borgersen, Lauge Østergaard, Jeppe K. Petersen, Niels E. Bruun, Peter E. Weeke, Søren L. Kristensen, Marianne Voldstedlund, Lars Køber, Emil L. Fosbøl

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.